BioSpace News Archive

EMulate Therapeutics, Inc. (EMulate) announced today the publication of its peer-reviewed clinical trial using EMulate’s technology for the treatment of glioblastoma in the Journal CNS Oncology https://www.futuremedicine.com/doi/10.2217/cns-2022-0016.

The product of Fosun Kite Biotechnology Co., Ltd., jointly established by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Kite Pharma of the United States (trade name: Yikaida®) for the treatment of adult large B-cell lymphoma (r/r LBCL) (“this new indication”) who failed first-line immunochemotherapy or relapsed within 12 months conditionally approved by the State Drug Administration (“NMPA”).